Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1992;80:127-131
© 1992 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HUCH, A.
Right arrow Articles by HUCH, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HUCH, A.
Right arrow Articles by HUCH, R.

Recombinant Human Erythropoietin in the Treatment of Postpartum Anemia

ALBERT HUCH, MD, KARL-HEINZ EICHHORN, MD, JAN DANKO, MD, PIERRE-ANDRÉ LAUENER, MD and RENATE HUCH, MD

From the Department of Obstetrics, University Hospital of Zurich, Zurich, Switzerland

Abstract

Postpartum maternal anemia (hemoglobin concentration below 10 g/dL) is a common problem in obstetrics. Human recombinant erythropoietin, which has been shown to correct the anemia of end-stage renal disease and eliminate the need for transfusions, was used in a comparative study of women with postpartum hemoglobin concentrations below 10 g/dL. Five daily doses of 4000IU were given. Hematologic and clinical data were compared on days 5, 14, and 42 after therapy in the treated women and in untreated women. Both groups received the same iron and folic acid supplements. Significantly greater increases in reticulocytes, hemoglobin, and hematocrit were seen by day 5 for the treated subjects compared with controls. Ferritin levels were significantly lower in the therapy group than in controls. No differences were seen between the groups in the platelet counts or clinical characteristics. No negative side effects were observed. As in other studies in populations without renal disease, recombinant human erythropoietin enhanced endogenous erythropoiesis over and above the normal physiologic recovery rate.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
J. A. Silverman, J. Barrett, and J. L. Callum
The Appropriateness of Red Blood Cell Transfusions in the Peripartum Patient
Obstet. Gynecol., November 1, 2004; 104(5): 1000 - 1004.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Obstetricians and Gynecologists.